Addressing Developmental Challenges of Gene Therapy Viral Vectors

Published on: 
, ,
Pharmaceutical Technology, Pharmaceutical Technology, Trends in Formulation, October 2022, Volume 2022 eBook, Issue 3
Pages: 36–40

Significant improvements have been developed to tackle the challenges in viral vector manufacturing at each stage.

Gene therapy has rapidly expanded conceptually and technically, now covering a wide array of tools and methods, including the advancement of viral vector delivery for gene therapies. Lentiviral vectors and adeno-associated virus (AAV) are two primary delivery mechanisms of gene therapies. While versatile and robust, there are some inherent weaknesses in the production of both AAV and lentivirus vectors, and, as a result, production is not well optimized. Over time, significant improvements have been developed to facilitate the manufacture of these viral vectors at each stage.

Read this article in Pharmaceutical Technology’s October 2022 Trends in Formulation eBook.


About the authors

Ger Brophy, is the executive vice-president of Biopharma Production, Arvind Srivastava is a technical fellow, Bioprocessing, and Greg Swan is business development manager for Cell & Gene Therapy; all are at Avantor.

Article Details

Pharmaceutical Technology
eBook: Trends in Formulation, October 2022
October 2022
Pages: 36–40


When referring to this article, please cite it as G. Brophy, A. Srivastava, and G.Swan, “Addressing Developmental Challenges of Gene Therapy Viral Vectors," Pharmaceutical Technology Trends in Formulation eBook (October 2022).